Voliotis Dimitris
Known title: SVP, Clinical DevelopmentCIK: 0001807910
Associated companies
Transaction History
| ZNTL | ▼ Sell | Open Market | 534 | $27K | 2/14/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 67 | $3K | 2/14/2022 | View on chart |
| ZNTL | ▲ Buy | Grant | 10,329 | $0 | 2/10/2022 | View on chart |
| ZNTL | ▲ Buy | Option Exercise | 10,000 | $180K | 1/20/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 8,343 | $505K | 1/20/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,657 | $101K | 1/20/2022 | View on chart |
| ZNTL | ▲ Buy | Option Exercise | 10,000 | $180K | 1/19/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 7,889 | $478K | 1/19/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,556 | $96K | 1/19/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 555 | $35K | 1/19/2022 | View on chart |
| ZNTL | ▲ Buy | Option Exercise | 10,000 | $180K | 1/18/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 3,409 | $210K | 1/18/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 3,294 | $205K | 1/18/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,997 | $127K | 1/18/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,300 | $84K | 1/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.